Debate on L1 for EGFR mut NSCLC : ‘easy osi’ then escalate to CT-ami, or use doublet upfront? Lazertinib+amivantmab likely to extend OS by ~ 1 yr vs osimertinib, but without cross over to CT-ami. Intensify only if ctEGFR not cleared after 4w of osi? #ELCC25

What can a test that identifies all previous viral infections in patients with lung cancer reveal about immunotherapy efficacy? #LCSM bit.ly/4fNuDDw